FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890113806> ?p ?o ?g. }

• W2890113806 abstract "e15592 Background: Molecular heterogeneity represents a significant hurdle in realizing precision medicine for gastric cancer (GC). Large-scale whole exome sequencing projects have identified distinct molecular subtypes to help define the heterogeneity of GC. However, it remains unclear whether the targeted gene panel-based sequencing can provide optimum targeted therapies and clinical utility in GC. The aim of this study is to generate comprehensive genomic profiling data and classify Japanese GC into actionable clusters associated with targeted therapies. Methods: FFPE tumor tissues were obtained from surgical or biopsy specimens of 207 Japanese patients with GC. Extracted DNA was subjected to genomic sequencing for 435 cancer related genes including 69 druggable genes with FDA approved targeted therapies. Somatic mutations, copy number alterations (SCNA), microsatellite instability (MSI) and Epstein-Barr virus (EBV) infection were evaluated using sequencing data. Results: Genomic sequencing identified at least one alteration of 435 genes in 194 pts (94%), and that of 69 druggable genes in 141 pts (68%). The most frequently altered druggable gene was ERBB2 (14%), following BRCA2 (11%) and ATM (10%). We successfully classified 207 tumors into four molecular subtypes, similar to the previously report; EBV (4%), MSI (8%), chromosomal instability (58%) and genomically stable subtype (30%). Frequent alterations of druggable genes ( > 5%) were widely observed through these subtypes. To discover the novel classifications associated with targeted therapies, we classified 207 tumors using mutation rate and hierarchical clustering. We identified a hypermutated group (n = 32), and a remaining non-hypermutated group (n = 175) which were sub-divided into six clusters including five actionable ones; ERBB2 (n = 25), CDKN2A and CDKN2B (n = 10), KRAS (n = 10), BRCA2 (n = 9) and ATM cluster (n = 12). Interestingly, we experienced a case of unresectable GC with a remarkable response for anti-HER2 therapy in the ERBB2 cluster. Conclusions: Genomic sequencing using a 435-gene panel has the potential to provide the information of optimum targeted therapies for upcoming precision medicine in Japanese GC." @default.
• W2890113806 created "2018-09-27" @default.
• W2890113806 creator A5007863504 @default.
• W2890113806 creator A5018112691 @default.
• W2890113806 creator A5019278166 @default.
• W2890113806 creator A5022874036 @default.
• W2890113806 creator A5027914167 @default.
• W2890113806 creator A5036289394 @default.
• W2890113806 creator A5038572461 @default.
• W2890113806 creator A5038860862 @default.
• W2890113806 creator A5046080544 @default.
• W2890113806 creator A5056655144 @default.
• W2890113806 creator A5056915467 @default.
• W2890113806 creator A5057255416 @default.
• W2890113806 creator A5060702089 @default.
• W2890113806 creator A5062655330 @default.
• W2890113806 creator A5063723368 @default.
• W2890113806 creator A5067160675 @default.
• W2890113806 creator A5073334746 @default.
• W2890113806 creator A5081160218 @default.
• W2890113806 creator A5081174788 @default.
• W2890113806 creator A5087348287 @default.
• W2890113806 date "2017-05-20" @default.
• W2890113806 modified "2023-09-22" @default.
• W2890113806 title "Genomic profiling using a 435-gene panel provides a vision for precision medicine in Japanese gastric cancer." @default.
• W2890113806 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15592" @default.
• W2890113806 hasPublicationYear "2017" @default.
• W2890113806 type Work @default.
• W2890113806 sameAs 2890113806 @default.
• W2890113806 citedByCount "0" @default.
• W2890113806 crossrefType "journal-article" @default.
• W2890113806 hasAuthorship W2890113806A5007863504 @default.
• W2890113806 hasAuthorship W2890113806A5018112691 @default.
• W2890113806 hasAuthorship W2890113806A5019278166 @default.
• W2890113806 hasAuthorship W2890113806A5022874036 @default.
• W2890113806 hasAuthorship W2890113806A5027914167 @default.
• W2890113806 hasAuthorship W2890113806A5036289394 @default.
• W2890113806 hasAuthorship W2890113806A5038572461 @default.
• W2890113806 hasAuthorship W2890113806A5038860862 @default.
• W2890113806 hasAuthorship W2890113806A5046080544 @default.
• W2890113806 hasAuthorship W2890113806A5056655144 @default.
• W2890113806 hasAuthorship W2890113806A5056915467 @default.
• W2890113806 hasAuthorship W2890113806A5057255416 @default.
• W2890113806 hasAuthorship W2890113806A5060702089 @default.
• W2890113806 hasAuthorship W2890113806A5062655330 @default.
• W2890113806 hasAuthorship W2890113806A5063723368 @default.
• W2890113806 hasAuthorship W2890113806A5067160675 @default.
• W2890113806 hasAuthorship W2890113806A5073334746 @default.
• W2890113806 hasAuthorship W2890113806A5081160218 @default.
• W2890113806 hasAuthorship W2890113806A5081174788 @default.
• W2890113806 hasAuthorship W2890113806A5087348287 @default.
• W2890113806 hasConcept C104317684 @default.
• W2890113806 hasConcept C111919701 @default.
• W2890113806 hasConcept C121608353 @default.
• W2890113806 hasConcept C126322002 @default.
• W2890113806 hasConcept C142724271 @default.
• W2890113806 hasConcept C143998085 @default.
• W2890113806 hasConcept C163763905 @default.
• W2890113806 hasConcept C187191949 @default.
• W2890113806 hasConcept C41008148 @default.
• W2890113806 hasConcept C54355233 @default.
• W2890113806 hasConcept C70721500 @default.
• W2890113806 hasConcept C71924100 @default.
• W2890113806 hasConcept C86803240 @default.
• W2890113806 hasConceptScore W2890113806C104317684 @default.
• W2890113806 hasConceptScore W2890113806C111919701 @default.
• W2890113806 hasConceptScore W2890113806C121608353 @default.
• W2890113806 hasConceptScore W2890113806C126322002 @default.
• W2890113806 hasConceptScore W2890113806C142724271 @default.
• W2890113806 hasConceptScore W2890113806C143998085 @default.
• W2890113806 hasConceptScore W2890113806C163763905 @default.
• W2890113806 hasConceptScore W2890113806C187191949 @default.
• W2890113806 hasConceptScore W2890113806C41008148 @default.
• W2890113806 hasConceptScore W2890113806C54355233 @default.
• W2890113806 hasConceptScore W2890113806C70721500 @default.
• W2890113806 hasConceptScore W2890113806C71924100 @default.
• W2890113806 hasConceptScore W2890113806C86803240 @default.
• W2890113806 hasLocation W28901138061 @default.
• W2890113806 hasOpenAccess W2890113806 @default.
• W2890113806 hasPrimaryLocation W28901138061 @default.
• W2890113806 hasRelatedWork W2011638877 @default.
• W2890113806 hasRelatedWork W2177941715 @default.
• W2890113806 hasRelatedWork W2559254066 @default.
• W2890113806 hasRelatedWork W2562446604 @default.
• W2890113806 hasRelatedWork W2562820441 @default.
• W2890113806 hasRelatedWork W2726361376 @default.
• W2890113806 hasRelatedWork W2757792275 @default.
• W2890113806 hasRelatedWork W2761067356 @default.
• W2890113806 hasRelatedWork W2765900471 @default.
• W2890113806 hasRelatedWork W2775396371 @default.
• W2890113806 hasRelatedWork W2803897487 @default.
• W2890113806 hasRelatedWork W2896878791 @default.
• W2890113806 hasRelatedWork W2900085021 @default.
• W2890113806 hasRelatedWork W2905783613 @default.
• W2890113806 hasRelatedWork W2946907398 @default.
• W2890113806 hasRelatedWork W2983333840 @default.
• W2890113806 hasRelatedWork W3002584672 @default.
• W2890113806 hasRelatedWork W3008657959 @default.
• W2890113806 hasRelatedWork W3031016840 @default.
• W2890113806 hasRelatedWork W3204574344 @default.

• next